Nature’s Sunshine results
This article was originally published in The Tan Sheet
Executive SummaryProvo, Utah-based firm's net sales jumped 28.3% to $88.3 mil. with net earnings up 58.9% to $4.7 mil. in the fourth quarter; year-end sales advanced 27.3% to $331 mil. as net income more than tripled to $17.1 mil. Nature's Sunshine domestic sales grew 7.7% in the fourth-quarter and maintained "strong momentum" in its Synergy Worldwide business and international operations, CEO Douglas Faggioli says. Quarterly gain is attributable to new products, such as Thai-Go liquid supplements, and marketing initiatives including the Habit of Health 90-Day Challenge...
You may also be interested in...
With $1.3bn invested in over 200 high-tech start-ups, OurCrowd is now sharpening its focus on medtech. Medtech Insight spoke to founder Jon Medved to find out more.
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.